Literature DB >> 18653463

The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells.

Thomas Y Wuest1, Jami Willette-Brown, Scott K Durum, Arthur A Hurwitz.   

Abstract

IL-2 is essential for CD4+CD25+forkhead box P3+ (FoxP3+) naturally occurring regulatory T cell (Treg) homeostasis and activation. Binding of IL-2 to its receptor leads to phosphorylation of STAT5, and binding of phosphorylated STAT5 to the foxp3 promoter increases foxp3 transcription, resulting in elevated levels of FoxP3 protein in Tregs. Transcriptional regulation by the elevated levels of FoxP3 is thought to be essential for the strong suppressor function seen in activated Tregs. IL-2 belongs to a family cytokines, which all depend on the common gamma-receptor chain (gammac). Given the well-documented effects of IL-2 on Treg function, the effect of other IL-2 family cytokines (IL-7, -15, and -21) on Tregs was examined. We observed that IL-7 and IL-15 induce STAT5 phosphorylation and up-regulation of FoxP3 in Tregs. STAT5 activation correlated with enhanced viability. However, only in the presence of IL-2 did Tregs acquire potent suppressor function. This finding is surprising, as IL-15 as well as IL-2 use the same IL-2R betac and gammac for signaling. In contrast, IL-21 activated STAT3 but did not activate STAT5 and had no effect on Treg viability, activation, or function. We therefore conclude that phosphorylation of STAT5, mediated through the IL-2Rgamma, promotes Treg survival in a resting and activated state. However, activation of STAT5 alone in conjunction with TCR signaling is not sufficient for the induction of potent suppressor function in Tregs, as IL-7 and IL-15 are not capable of inducing potent Treg suppressor function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18653463      PMCID: PMC2538590          DOI: 10.1189/jlb.1107778

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  50 in total

1.  Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.

Authors:  A M Thornton; E M Shevach
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha.

Authors:  Denis Franchimont; Jérôme Galon; Melanie S Vacchio; Samuel Fan; Roberta Visconti; David M Frucht; Vincent Geenen; George P Chrousos; Jonathan D Ashwell; John J O'Shea
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

3.  Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.

Authors:  M Itoh; T Takahashi; N Sakaguchi; Y Kuniyasu; J Shimizu; F Otsuka; S Sakaguchi
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

4.  Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.

Authors:  Erwan Mortier; Agnès Quéméner; Patricia Vusio; Inken Lorenzen; Yvan Boublik; Joachim Grötzinger; Ariane Plet; Yannick Jacques
Journal:  J Biol Chem       Date:  2005-11-11       Impact factor: 5.157

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist.

Authors:  Chia-Huey Lin; Thomas Hünig
Journal:  Eur J Immunol       Date:  2003-03       Impact factor: 5.532

7.  Possible mechanism for the alpha subunit of the interleukin-2 receptor (CD25) to influence interleukin-2 receptor signal transduction.

Authors:  Jonathan M Ellery; Peter J Nicholls
Journal:  Immunol Cell Biol       Date:  2002-08       Impact factor: 5.126

8.  Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen.

Authors:  I Förster; R Hirose; J M Arbeit; B E Clausen; D Hanahan
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

9.  Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells.

Authors:  Daniel T Patton; Oliver A Garden; Wayne P Pearce; Louise E Clough; Clare R Monk; Eva Leung; Wendy C Rowan; Sara Sancho; Lucy S K Walker; Bart Vanhaesebroeck; Klaus Okkenhaug
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

10.  The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro.

Authors:  John Yates; Flavia Rovis; Peter Mitchell; Behdad Afzali; J Y-S Tsang; Marina Garin; R I Lechler; Giovanna Lombardi; O A Garden
Journal:  Int Immunol       Date:  2007-06-01       Impact factor: 4.823

View more
  42 in total

1.  Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly.

Authors:  Anandharaman Veerapathran; Joseph Pidala; Francisca Beato; Xue-Zhong Yu; Claudio Anasetti
Journal:  Blood       Date:  2011-09-23       Impact factor: 22.113

2.  An in vivo IL-7 requirement for peripheral Foxp3+ regulatory T cell homeostasis.

Authors:  Grace Y Kim; Davinna L Ligons; Changwan Hong; Megan A Luckey; Hilary R Keller; Xuguang Tai; Philip J Lucas; Ronald E Gress; Jung-Hyun Park
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

3.  Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells.

Authors:  Irina V Pinchuk; Ellen J Beswick; Jamal I Saada; Gushyalatha Boya; David Schmitt; Gottumukkala S Raju; Julia Brenmoehl; Gerhard Rogler; Victor E Reyes; Don W Powell
Journal:  Gastroenterology       Date:  2011-03-02       Impact factor: 22.682

4.  Regulatory T cells limit unconventional memory to preserve the capacity to mount protective CD8 memory responses to pathogens.

Authors:  Andreia S Da Costa; Jessica B Graham; Jessica L Swarts; Jennifer M Lund
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-29       Impact factor: 11.205

5.  CD4 effector T cell differentiation is controlled by IL-15 that is expressed and presented in trans.

Authors:  Adam T Waickman; Davinna L Ligons; SuJin Hwang; Joo-Young Park; Vanja Lazarevic; Noriko Sato; Changwan Hong; Jung-Hyun Park
Journal:  Cytokine       Date:  2017-08-12       Impact factor: 3.861

Review 6.  The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Authors:  Frank Cichocki; Michael R Verneris; Sarah Cooley; Veronika Bachanova; Claudio G Brunstein; Bruce R Blazar; John Wagner; Heinrich Schlums; Yenan T Bryceson; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

7.  Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates.

Authors:  Timothy Millington; Maria Koulmanda; Choo Ng; Svjetlan Boskovic; Ognjenka M Nadazdin; Gilles Benichou; Xin Xiao Zheng; Terry B Strom; Joren C Madsen
Journal:  J Heart Lung Transplant       Date:  2012-02-24       Impact factor: 10.247

8.  Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.

Authors:  Serena K Perna; Biagio De Angelis; Daria Pagliara; Sayyeda T Hasan; Lan Zhang; Aruna Mahendravada; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Gianpietro Dotti; Barbara Savoldo
Journal:  Clin Cancer Res       Date:  2012-11-13       Impact factor: 12.531

9.  The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins.

Authors:  V D K D Sewgobind; L J W van der Laan; M M L Kho; R Kraaijeveld; S S Korevaar; W Mol; W Weimar; C C Baan
Journal:  Clin Exp Immunol       Date:  2010-05-28       Impact factor: 4.330

Review 10.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.